ABT-888 (Veliparib): Potent PARP1/2 Inhibitor for Cancer DNA Repair Research

Executive Summary: ABT-888 (Veliparib) is a potent and selective inhibitor of PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM), enzymes critical for DNA single-strand break repair (APExBIO). Inhibition of PARP activity sensitizes tumor cells to cytotoxic chemotherapy and radiation, especially in models with microsatellite instability (MSI) and DNA repair gene mutations (Unlocking the Translational Power of ABT-888). ABT-888 demonstrates high in vivo efficacy in preclinical colorectal cancer xenografts by synergizing with SN38 and oxaliplatin. Stock solutions are prepared in DMSO (>10 mM), and the compound's purity (>99.5%) is confirmed by HPLC and NMR. The product is intended for research use only and is supplied by APExBIO.

Biological Rationale

DNA repair is essential for genomic stability. Poly (ADP-ribose) polymerase enzymes (PARP1/2) detect and initiate repair of single-strand DNA breaks. Inhibiting PARP activity results in accumulation of unrepaired DNA damage, ultimately leading to cell death, particularly in cells deficient in homologous recombination repair (HRR). Tumor models with microsatellite instability (MSI) or mutations in DNA repair genes such as MRE11 and RAD50 are especially susceptible to PARP inhibition (Pettenger-Willey et al., 2026). This provides a strong rationale for combining PARP inhibitors like ABT-888 with DNA-damaging agents in cancer research.

Mechanism of Action of ABT-888 (Veliparib)

ABT-888 (Veliparib) binds to and inhibits the catalytic activity of PARP1 and PARP2 at nanomolar concentrations (Ki = 5.2 nM for PARP1, 2.9 nM for PARP2) (APExBIO). PARP1/2 are responsible for detecting and signaling single-strand DNA breaks. Inhibition prevents PARP-mediated poly (ADP-ribosyl)ation, impairing DNA damage repair and increasing DNA strand breaks. In HRR-deficient cells, this leads to synthetic lethality. ABT-888 thereby enhances the cytotoxic effects of agents like SN38 and oxaliplatin in preclinical tumor models.

Evidence & Benchmarks

• ABT-888 inhibits PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM) enzymatic activity in vitro under standard buffer conditions (20°C, pH 7.4) (APExBIO).
• In colorectal cancer xenograft models with MSI and MRE11/RAD50 mutations, ABT-888 in combination with SN38 or oxaliplatin significantly delayed tumor growth (p < 0.01) (Unlocking the Translational Power of ABT-888).
• PARP inhibitors, including ABT-888, did not significantly alter calicheamicin-induced cytotoxicity in acute leukemia cell lines in a recent genome-wide screen, supporting pathway specificity (Pettenger-Willey et al., 2026).
• ABT-888 is highly pure (>99.5%) as validated by high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy (APExBIO).
• Stock solutions remain stable at -20°C for short-term experimental use; long-term storage is not recommended (APExBIO).

Applications, Limits & Misconceptions

ABT-888 is widely deployed in preclinical research on DNA repair inhibition, chemotherapy sensitization, and synthetic lethality studies. Its effects are most pronounced in tumor cell lines with defective DNA repair pathways or high MSI. However, recent evidence from acute leukemia studies indicates that PARP inhibition does not universally sensitize all cancer types to DNA-damaging agents, underscoring the importance of genetic context (Pettenger-Willey et al., 2026).

For a broader mechanistic exploration, see ABT-888 (Veliparib): Advanced Mechanisms and Next-Gen Applications, which details molecular interactions but does not provide experimental stability data, as clarified here. For strategic insights on protocol optimization, consult Scenario-Driven Solutions with ABT-888 (Veliparib); this article further specifies quantitative stability and storage parameters. Our synthesis here updates these works with recent findings on tissue and pathway specificity.

Common Pitfalls or Misconceptions

• PARP inhibition by ABT-888 does not enhance chemotherapy sensitivity in all cancer types; acute leukemia models show limited synergy (Pettenger-Willey et al., 2026).
• ABT-888 is not suitable for diagnostic or therapeutic use in humans; it is for research use only (APExBIO).
• Long-term storage of ABT-888 solutions at -20°C is not recommended due to potential degradation (APExBIO).
• Solubility in water is negligible; DMSO or ethanol are required as solvents for stock preparation.
• Effectiveness may depend on the presence of DNA repair gene mutations (e.g., MRE11, RAD50) or MSI status.

Workflow Integration & Parameters

ABT-888 is supplied as a solid with molecular weight 244.3 and formula C13H16N4O. It is insoluble in water; stock solutions should be prepared in DMSO (≥10 mM, with warming and ultrasonic treatment as needed) or ethanol (≥10.6 mg/mL with ultrasound). Use immediately or store at -20°C for short-term application. Solutions should not be kept for more than several weeks. Experimental protocols typically involve pre-incubation with ABT-888 for 1–2 hours prior to adding DNA-damaging agents. For optimal results, ensure cell models exhibit MSI or DNA repair gene mutations. Quality is validated by HPLC and NMR, with guaranteed purity >99.5% (APExBIO).

Conclusion & Outlook

ABT-888 (Veliparib) is a benchmark tool for investigating the role of PARP-mediated DNA repair in cancer models, with proven utility in MSI and DNA repair-deficient tumor systems. While it robustly synergizes with certain chemotherapeutic agents in colorectal and other solid tumor research, its utility in hematologic malignancies is context-dependent. Ongoing research and genome-wide screens will continue to refine its optimal application. For product specifications and ordering, refer to the ABT-888 (Veliparib) A3002 kit from APExBIO.